Thromboembolic events associated with thalidomide and multimodality therapy for soft tissue sarcomas: Results of RTOG 0330

J. M. Kane, J. Harris, W. G. Kraybill, D. C. Harmon, D. S. Ettinger, D. R. Lucas, T. F. Delaney, D. Wang, W. J. Curran, B. L. Eisenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction. RTOG 0330 was developed to address the toxicity of RTOG 9514 and to add thalidomide (THAL) to MAID chemoradiation for intermediate/high grade soft tissue sarcomas (STSs) and to preoperative radiation (XRT) for low-grade STS. Methods. Primary/locally recurrent extremity/trunk STS: ≥8cm, intermediate/high grade (cohort A): 5cm, low grade (cohort B). Cohort A: 3 cycles of neoadjuvant MAID, 2 cycles of interdigitated THAL (200mg/day)/ concurrent 22 Gy XRT, resection, 12 months of adjuvant THAL. Cohort B: neoadjuvant THAL/concurrent 50Gy XRT, resection, 6 months of adjuvant THAL. Planned accrual 44 patients. Results. 22 primary STS patients (cohort A/B 15/7). Cohort A/B: median age of 49/47 years; median tumor size 12.8/10cm. 100 preoperative THAL/XRT and surgical resection. Three cycles of MAID were delivered in 93 cohort A. Positive margins: 27 cohort A/29 cohort B. Adjuvant THAL: 60 cohort A/57 cohort B. Grade 3/4 venous thromboembolic (VTE) events: 40 cohort A (1 catheter thrombus and 5 DVT or PE) versus 0 cohort B. RTOG 0330 closed early due to cohort A VTE risk and cohort B poor accrual. Conclusion. Neoadjuvant MAID with THAL/XRT was associated with increased VTE events not seen with THAL/XRT alone or in RTOG 9514 with neoadjuvant MAID/XRT.

Original languageEnglish (US)
Article number659485
JournalSarcoma
Volume2012
DOIs
StatePublished - 2012

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Thromboembolic events associated with thalidomide and multimodality therapy for soft tissue sarcomas: Results of RTOG 0330'. Together they form a unique fingerprint.

Cite this